(Q51072895)

28 March 2018

title

A prospective evaluation of VEGF-targeted treatment cessation in metastatic clear cell renal cancer. (English)

1 reference

28 March 2018

author

Grant D. Stewart

6

1 reference

28 March 2018

Daniel Berney

7

1 reference

28 March 2018

author name string

T Powles

1

1 reference

28 March 2018

I Kayani

2

1 reference

28 March 2018

K Sharpe

3

1 reference

28 March 2018

L Lim

4

1 reference

28 March 2018

J Peters

5

1 reference

28 March 2018

A Sahdev

8

1 reference

28 March 2018

S Chowdhury

9

1 reference

28 March 2018

E Boleti

10

1 reference

28 March 2018

J Shamash

11

1 reference

28 March 2018

A R Reynolds

12

1 reference

28 March 2018

R Jones

13

1 reference

28 March 2018

C Blank

14

1 reference

28 March 2018

J Haanen

15

1 reference

28 March 2018

A Bex

16

1 reference

28 March 2018

publication date

11 April 2013

1 reference

28 March 2018

published in

Annals of Oncology

1 reference

28 March 2018

volume

24

1 reference

28 March 2018

issue

8

1 reference

28 March 2018

page(s)

2098-2103

1 reference

28 March 2018

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT130

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT130

Complete remission with tyrosine kinase inhibitors in renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT130

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT130

Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT130

The reverse side of the victory: flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT130

The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT130

Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT130

Contrasting effects of sunitinib within in vivo models of metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT130

Outcome of treatment discontinuation in patients with metastatic renal cell carcinoma and no evidence of disease following targeted therapy with or without metastasectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT130

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDT130

1 reference

28 March 2018

1 reference

28 March 2018